NASH PASS clinical trial enrollment initiative gains partner

High Point Clinical Trials Center announced a 3-year collaboration with ProSciento to join NASH PASS as a site partner, according to a press release.

NASH PASS is Prosciento’s program designed to combine select qualified sites and a proprietary methodology to improve enrollment outcomes in nonalcoholic steatohepatitis clinical trials.

As a partner in NASH PASS, High Point Clinical Trials Center (HPCTC) will contribute its pharmacology expertise and resources from its database of prospective clinical study participants evaluated for nonalcoholic fatty liver disease and NASH using transient elastography, proprietary algorithms and noninvasive biomarker testing.

“This collaboration is an ideal alignment between best in class organizations focused on providing early clinical proof of concept study design and execution in the NAFLD and NASH disease space,” Clay Dehn, vice president of clinical pharmacology services at HPCTC, said in the release. “Our consultative approach ensures that the correct endpoints are incorporated into the study design and with ProSciento we are well-positioned to support enriched clinical enrollment for those studies.”

Reference: www.prosciento.com

High Point Clinical Trials Center announced a 3-year collaboration with ProSciento to join NASH PASS as a site partner, according to a press release.

NASH PASS is Prosciento’s program designed to combine select qualified sites and a proprietary methodology to improve enrollment outcomes in nonalcoholic steatohepatitis clinical trials.

As a partner in NASH PASS, High Point Clinical Trials Center (HPCTC) will contribute its pharmacology expertise and resources from its database of prospective clinical study participants evaluated for nonalcoholic fatty liver disease and NASH using transient elastography, proprietary algorithms and noninvasive biomarker testing.

“This collaboration is an ideal alignment between best in class organizations focused on providing early clinical proof of concept study design and execution in the NAFLD and NASH disease space,” Clay Dehn, vice president of clinical pharmacology services at HPCTC, said in the release. “Our consultative approach ensures that the correct endpoints are incorporated into the study design and with ProSciento we are well-positioned to support enriched clinical enrollment for those studies.”

Reference: www.prosciento.com